Full history for every metric is available with a Kvantra account
Ceapro Inc. (CRPOF)
Key financial summary
Financials in CAD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CAD m | 12 | 13 | 15 | 17 | 19 | 10 | 9 |
| Operating profit | CAD m | -6 | -8 | |||||
| Net profit | CAD m | -0 | -1 | 2 | 3 | 4 | -5 | -6 |
| EPS reported | CAD | -0.06 | -0.08 | |||||
| Operating cashflow per share | CAD | -0.05 | -0.05 | |||||
| Capex per share | CAD | 0.01 | 0.01 | |||||
| FCF per share | CAD | -0.06 | -0.06 | |||||
| Free cash flow | CAD m | -5 | -7 | |||||
| Net debt | CAD m | -7 | -4 | |||||
| Book value equity | CAD m | 28 | 26 | |||||
| Book value per share | CAD | 0.36 | 0.33 | |||||
| Number of shares | m | 78.27 | 78.29 | |||||
| DPS (TTM paid) | CAD | 0.00 | 0.00 |
Financial summary
Financials in CAD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 26.00 | 0.73 | |||||
| P/S LTM | x | 75.19 | 2.13 | |||||
| P/FCF LTM | x | -157.34 | -2.55 | |||||
| EV/EBITDA LTM | x | -187.42 | -2.51 | |||||
| EV/Sales LTM | x | 74.51 | 1.64 | |||||
| Earnings Yield LTM | % | -0.65% | -24.86% | |||||
| FCF Yield | % | -0.64% | -39.23% | |||||
| Quality | ||||||||
| ROE | % | -16.91% | -15.66% | |||||
| ROIC | % | -16.57% | -16.57% | |||||
| Operating margin | % | -64.93% | -64.93% | |||||
| Gross margin | % | 36.99% | 36.99% | |||||
| FCF/Sales | % | -47.79% | -47.79% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -48.87% | -44.86% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -2.05 | -3.46 | |||||
| Net Debt/EBITDA | x | 1.72 | 1.72 | |||||
| EBIT/Net interest | x | -48.82 | -48.82 | |||||
| Net debt/market cap | % | -0.91% | -22.92% | |||||
| Net debt/Equity | x | -0.24 | -0.17 | |||||
| Gross debt/equity | x | 0.08 | 0.08 | |||||
Company overview
Operating as a biotechnology enterprise, Ceapro Inc. is dedicated to pioneering and bringing to market health and wellness offerings, alongside their underlying technologies, which are all predicated on plant-derived compounds. Its commercial reach extends across the United States, Germany, China, Canada, and various other global markets. The company's operations are divided into two principal sectors. The first, its Active Ingredient Product Technology division, is centered on inventing and employing exclusive extraction methodologies. These are utilized for the manufacturing, refinement, and sale of potent substances like oat beta glucan and avenanthramides, extracted from oats and other sustainable botanical sources, serving both the healthcare and beauty industries. Conversely, the Cosmeceutical Industry segment concentrates on the creation and commercial release of anti-aging goods. These products, formulated from natural active components, are primarily distributed straight to consumers through the company's online portal and via a network of specialized natural product retailers. Established in 1997, Ceapro Inc.'s main corporate office is located in Edmonton, Canada.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Ceapro Inc. (CRPOF)
Operating as a biotechnology enterprise, Ceapro Inc. is dedicated to pioneering and bringing to market health and wellness offerings, alongside their underlying technologies, which are all predicated on plant-derived compounds. Its commercial reach extends across the United States, Germany, China, Canada, and various other global markets. The company's operations are divided into two principal sectors. The first, its Active Ingredient Product Technology division, is centered on inventing and employing exclusive extraction methodologies. These are utilized for the manufacturing, refinement, and sale of potent substances like oat beta glucan and avenanthramides, extracted from oats and other sustainable botanical sources, serving both the healthcare and beauty industries. Conversely, the Cosmeceutical Industry segment concentrates on the creation and commercial release of anti-aging goods. These products, formulated from natural active components, are primarily distributed straight to consumers through the company's online portal and via a network of specialized natural product retailers. Established in 1997, Ceapro Inc.'s main corporate office is located in Edmonton, Canada.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free